AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28597973
Drug: 4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/day OM3‐CA
Trial: 23312683
Drug: Low-flow nasal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flow nasal prongs therapy with room air (1 L/min)
Trial: 20698734
Drug: Daily salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily salt intake (18.01 g/day)
Trial: 14597872
Drug: Paclitaxel (PAC)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (PAC) 100 mg/m2 infused over 1 hour
Trial: 14597872
Drug: Paclitaxel (PAC)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (PAC) 100 mg/m2 infused over 3 hours
Trial: 7502550
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (750 mg per day)
Trial: 7502550
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (750 mg per day) + Simvastatin (20 mg per day)
Trial: 7502550
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg per day)
Trial: 30352226
Drug: Binocular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binocular treatment with the dichoptic binocular Dig Rush iPad game (1 hour per day, 5 days per week) for 8 weeks
Trial: 30352226
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of binocular treatment vs. control
Trial: 29225440
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch use
Trial: 24069481
Drug: Twice-daily application
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily application of the plant-based repellent Zanzarin
Trial: 21771745
Drug: Mixed oral
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed oral nutritional supplements containing B‐group vitamins
Trial: 19448230
Drug: i.t. morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.t. morphine (4 microg/kg)
Trial: 19448230
Drug: i.t. morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.t. morphine and clonidine (1 microg/kg)
Trial: 9213082
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of sulpiride
Trial: 7960687
Drug: nizatidine 300
RxNorm normalized name: nizatidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nizatidine 300 mg, once nightly for 4 weeks
Trial: 23208457
Drug: Transtympanic steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transtympanic steroid injection plus conventional steroid treatment (TR group, n=27)
Trial: 23208457
Drug: Conventional steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional steroid treatment (Control group, n=26)
Trial: 20650039
Drug: Non-concurrent amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-concurrent amlodipine dosing (simvastatin at 7:00 PM followed by amlodipine at 11:00 PM)
Trial: 20650039
Drug: Concurrent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent dosing (both drugs at 7:00 PM)
Trial: 20650039
Drug: Non-concurrent amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-concurrent amlodipine dosing
Trial: 20650039
Drug: Concurrent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent dosing
Trial: 20650039
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (non-concurrent and concurrent)
Trial: 17764004
Drug: Self-therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-therapy
Trial: 8806331
Drug: Prehospital thrombolytic
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehospital thrombolytic therapy (recombinant tissue plasminogen activator)
Trial: 8806331
Drug: Hospital thrombolytic
RxNorm normalized name: THROMBOLYTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital thrombolytic therapy (recombinant tissue plasminogen activator)
Trial: 8806331
Drug: Prehospital thrombolytic
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehospital thrombolytic therapy
Trial: 8806331
Drug: Hospital thrombolytic
RxNorm normalized name: THROMBOLYTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital thrombolytic therapy
Trial: 8806331
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy within < 70 minutes from symptom onset
Trial: 8806331
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy after 70 minutes from symptom onset
Trial: 6397969
Drug: De-Nol liquid
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De-Nol liquid (4 X 5 ml)
Trial: 6397969
Drug: Sucralfate (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (4 X 1 g)
Trial: 6397969
Drug: Pirenzepine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (3 X 50 mg)
Trial: 30955915
Drug: Tipapkinogen sovacivec
RxNorm normalized name: Tipapkinogene sovacivec
DrugBank: Tipapkinogene sovacivec (DB06239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tipapkinogen sovacivec (TS) vaccine
Trial: 25099983
Drug: Live saxophone
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live saxophone music therapy for 30 minutes
Trial: 21924651
Drug: Azithromycin monotherapy
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin monotherapy orally
Trial: 21924651
Drug: Azithromycin in
RxNorm normalized name: azithromycin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin in combination with rifampin orally
Trial: 20433566
Drug: New daytime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New daytime at-home bleaching system (28% carbamide peroxide gel) with a non-custom-fit tray for 20 minutes
Trial: 20433566
Drug: Conventional overnight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional overnight at-home bleaching system (10% carbamide peroxide gel) with a custom-fit tray for 6 to 8 hours
Trial: 16189335
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg x kg(‐1) ketamine (Group K)
Trial: 16189335
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg x kg(‐1) ketamine and 0.25% bupivacaine (Group BK)
Trial: 12378045
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg oral ascorbic acid (AA) preoperatively
Trial: 10434238
Drug: Bosentan (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (500 mg twice daily for 10 days)
Trial: 10434238
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily for 10 days)
Trial: 1971741
Drug: Diphenhydramine 50
RxNorm normalized name: diphenhydrAMINE 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine 50 mg (positive control)
Trial: 29412076
Drug: Nitrate-rich beetroot
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-rich beetroot juice (BR; ∼800 mg/d)
Trial: 29412076
Drug: Nitrate-depleted beetroot
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-depleted beetroot juice (PLA; ∼0.5 mg/d)
Trial: 12034031
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) monotherapy
Trial: 18030234
Drug: Interferon plus
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon plus lamivudine combination therapy
Trial: 12043854
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation suspension 0.5 mg twice daily
Trial: 12798837
Drug: Management group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management group (daily weight monitoring)
Trial: 7560229
Drug: Saline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline and alcohol solutions
Trial: 2020505
Drug: Soy-based, lactose-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy-based, lactose-free formula alternating with oral rehydration solution (early feeding)
Trial: 2020505
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solution alone (control group)
Trial: 6760074
Drug: H1 antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: H1 antagonist (diphenhydramine 50 mg iv)
Trial: 6760074
Drug: H2 antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: H2 antagonist (cimetidine 300 mg iv)
Trial: 21360596
Drug: Aripiprazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (15 mg, single oral dose)
Trial: 19532050
Drug: New ART
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New ART agents and fixed-dose combinations
Trial: 15122774
Drug: Synbiotic preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic preparation (n = 20)
Trial: 9116392
Drug: Cyclical etidronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclical etidronate therapy (n = 61)
Trial: 6365873
Drug: Imipenem-cilastatin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem-cilastatin (250 mg 6 hourly iv)
Trial: 6365873
Drug: Cefazolin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (1000 mg 6 hourly iv)
Trial: 26454322
Drug: Intravenous haemocoagulase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous haemocoagulase
Trial: 15860476
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy intervention consisting of six sessions and maintenance phase with one home and three brief telephone sessions
Trial: 8558671
Drug: 5 ml.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml. 1% lidocaine
Trial: 8558671
Drug: 5 ml.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml. saline (0.9% sodium chloride)
Trial: 1678700
Drug: Vecuronium (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.1 mg kg‐1)
Trial: 1678700
Drug: Atracurium (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (0.5 mg kg‐1)
Trial: 6389815
Drug: Soluble aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble aspirin given by mouth in divided dosage
Trial: 31617926
Drug: Active interventions
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active interventions (physical exercise, nutritional enhancement, cognitive training, combined treatment)
Trial: 24354913
Drug: Linguistic agency
RxNorm normalized name: ALCOHOL 75 mL in 100 g TOPICAL CLOTH [Greenfield Agencies Alcohol Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linguistic agency assigned to HPV (e.g., 'HPV preys on millions of people')
Trial: 24354913
Drug: Linguistic agency
RxNorm normalized name: ALCOHOL 75 mL in 100 g TOPICAL CLOTH [Greenfield Agencies Alcohol Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linguistic agency assigned to vaccination (e.g., 'Vaccination guards people')
Trial: 22405597
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg/day) for 2 years
Trial: 20670438
Drug: Intracarpal injections
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracarpal injections of 1 ml triamcinolonacetonide 10 mg/ml (TCA)
Trial: 20670438
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml NaCl (placebo)
Trial: 17379125
Drug: Traditional tidal
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional tidal volume ventilation (V(T), 10 mL/kg)
Trial: 17379125
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume ventilation (V(T), 6 mL/kg)
Trial: 17378787
Drug: TCI-propofol and
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TCI-propofol and intravenously administered ketamine (n=9)
Trial: 9116609
Drug: i.v. acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. acyclovir 500 mg/m2 three times a day from 5 days before transplant to 30 days after transplant followed by oral acyclovir 800 mg four times a day for a further 6 months
Trial: 9116609
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg oral acyclovir four times a day followed by placebo (control)
Trial: 3921097
Drug: Myringotomy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myringotomy and antibiotics combined
Trial: 3921097
Drug: Nose drops
RxNorm normalized name: Nose Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nose drops and analgesics
Trial: 1097603
Drug: Phenothiazine (+/‐)‐10‐3‐dimethylamino‐2‐methylpropyl)‐2‐valeroylphenothiazine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenothiazine (+/‐)‐10‐3‐dimethylamino‐2‐methylpropyl)‐2‐valeroylphenothiazine, 40 mg daily
Trial: 31232274
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) of nifedipine GITS 60 mg and candesartan 32 mg
Trial: 31232274
Drug: Loose combination
RxNorm normalized name: loose wheat smut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loose combination of nifedipine and candesartan
Trial: 30279197
Drug: Single antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single antiplatelet therapy (SAPT) - aspirin only
Trial: 30279197
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) for an additional six months
Trial: 24356620
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (DA) 500 µg q3w
Trial: 19942640
Drug: 520 mg
RxNorm normalized name: aspirin 520 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 520 mg cocoa flavanols (CF)
Trial: 19942640
Drug: 994 mg
RxNorm normalized name: petrolatum 0.994 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 994 mg cocoa flavanols (CF)
Trial: 12045677
Drug: Chronic suppressive
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic suppressive fluconazole therapy
Trial: 12045677
Drug: Episodic fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Episodic fluconazole therapy
Trial: 8545290
Drug: Nilvadipine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilvadipine (4 mg)
Trial: 12811943
Drug: Protein-rich liquid
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-rich liquid supplementation with anabolic steroid
Trial: 6611964
Drug: 15-methyl PGF2
RxNorm normalized name: 15-methyl-pgf2.alpha.
DrugBank: Carboprost (DB19356)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15-methyl PGF2 alpha with indomethacin suppositories before and during PG induction
Trial: 24911423
Drug: Telephone-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-delivered cognitive behavioral therapy (CBT) intervention for 8 weeks
Trial: 19711113
Drug: Natalizumab treatment
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Natalizumab treatment for 12 months
Trial: 12127707
Drug: Lomefloxacin (LOMX)
DrugBank: Lomefloxacin (DB00978)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lomefloxacin (LOMX) 400 mg once daily
Trial: 12127707
Drug: Ciprofloxacin (CIPX)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (CIPX) 500 mg twice daily
Trial: 9771414
Drug: Lipid solution
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid solution (1 ml/minute for 30 minutes)
Trial: 9771414
Drug: Protein solution
RxNorm normalized name: Plasma protein solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein solution (4.18 J/ml)
Trial: 9771414
Drug: Non-absorbable electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-absorbable electrolyte solution containing polyethylene glycol
Trial: 7934538
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (pravastatin, nicotinic acid, cholestyramine, and gemfibrozil)
Trial: 3282033
Drug: Fluorouracil (5‐FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil (5‐FU) 15 mg/kg/wk
Trial: 3282033
Drug: Fluorouracil (5‐FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil (5‐FU) plus cisplatin (60 mg/m2 every 3 weeks)
Trial: 30807835
Drug: ICG-based adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICG-based adjunctive antimicrobial photodynamic therapy (aPDT) with perio green® 0.1 mg/ml and diode laser at 808 nm (100 mW at 2 kHz)
Trial: 18179308
Drug: Multi-Family Psychoeducation
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-Family Psychoeducation Groups (MFPGs), 8-session manual-driven treatment as an adjunct to current medications and psychotherapy.
Trial: 16306721
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous opioid
Trial: 30574864
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) of gemigliptin 50 mg and metformin 500 mg
Trial: 30574864
Drug: Loose combination
RxNorm normalized name: loose wheat smut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loose combination of gemigliptin 50 mg and metformin 500 mg
Trial: 30664989
Drug: Chemotherapy (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (up to 6 cycles of topotecan or re-induction of initial chemotherapy)
Trial: 28387891
Drug: Scopolamine butylbromide
RxNorm normalized name: Scopolamine butylbromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine butylbromide (intramuscular injection before operation)
Trial: 28387891
Drug: No preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preoperative intramuscular injection (control group)
Trial: 19706089
Drug: pimecrolimus 1%
RxNorm normalized name: PIMECROLIMUS 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pimecrolimus 1% cream plus microdermabrasion
Trial: 19706089
Drug: pimecrolimus 1%
RxNorm normalized name: PIMECROLIMUS 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pimecrolimus 1% cream alone
Trial: 15561650
Drug: MTZ/CTX 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTZ/CTX 1 g once daily
Trial: 15561650
Drug: T/C 3.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T/C 3.1 g every 6 hours
Trial: 11557914
Drug: Reboxetine 2
RxNorm normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine 2 mg
Trial: 11557914
Drug: Reboxetine 4
RxNorm normalized name: reboxetine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine 4 mg
Trial: 11557914
Drug: Reboxetine 6
RxNorm normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine 6 mg
Trial: 11557914
Drug: Reboxetine 6
RxNorm normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine 6 mg with 200 mg ketoconazole
Trial: 9631989
Drug: Fluconazole 300
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole 300 mg once weekly
Trial: 9631989
Drug: Fluconazole 450
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole 450 mg once weekly
Trial: 28941842
Drug: Cold gel
RxNorm normalized name: Deep Freeze Cold Gel
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold gel packs